NewEdge Advisors’s Lisata Therapeutics LSTA Stock Holding History

NewEdge Advisors’s Portfolio LSTA Stock Details LSTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-107	Closed	-$199	–	4282
2025 Q4	$199	Buy	+107	New	+$238	﹤0.01%	4131

Other funds holding LSTA

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DAM

Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return

Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

NewEdge Advisors's LSTA Position: Q1 2026 in Review

NewEdge Advisors sold out of Lisata Therapeutics (LSTA) in Q1 2026, closing a stake of 107 shares — an estimated $199 sold.

NewEdge Advisors first reported a position in LSTA in Q4 2025 and held it in 1 quarter. The position peaked at $199 in Q4 2025. 34 funds tracked by Wall St. Rank hold LSTA as of Q1 2026.

NewEdge Advisors reported no remaining Lisata Therapeutics position as of Q1 2026 after selling out during the quarter.
NewEdge Advisors sold 107 Lisata Therapeutics shares in Q1 2026, an estimated $199.
NewEdge Advisors first reported a position in Lisata Therapeutics in Q4 2025 and held it in 1 quarter.
NewEdge Advisors's Lisata Therapeutics position peaked at $199 in Q4 2025.
34 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.